CCL2 and neoplasm: When CCL2 binds to its receptors on T cells, it can increase the expression of PD-1/PD-L1, thereby influencing treatment efficacy.[41] Zhu’s study demonstrated that patients with LUAD exhibiting high neutrophil content had significantly worse prognosis, potentially due to the more active BPs linked to tumor progression.[42] Liu XL developed an NRG-based prognostic model for LUAD, exploring its influence on tumorigenesis and progression through the SNHG14/hsa-miR-101-3p/KL/PLK1 signaling axis.